Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New antithrombotic agents.

R Castelli1, F Porro, D Savo

  • 1Department of Internal Medicine and Medical Specialties, Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Foundation, IRCCS, Via Francesco Sforza 35, 20122 Milan, Italy. Castelli39@interfree.it

Panminerva Medica
|January 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Salt dependent aquagenic urticaria: nine new cases and proposal for a diagnostic work-up.

European annals of allergy and clinical immunology·2024
Same author

Long-term clinical efficacy and safety of ixekizumab for psoriatic patients: a single-center experience.

European review for medical and pharmacological sciences·2023
Same author

Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects.

Annals of hematology·2022
Same author

Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course.

Clinical and experimental immunology·2020
Same author

Bone strain index reproducibility and soft tissue thickness influence: a dual x-ray photon absorptiometry phantom study.

European radiology experimental·2019
Same author

Assessment of climate change effects on mountain ecosystems through a cross-site analysis in the Alps and Apennines.

The Science of the total environment·2018
Same journal

Circulating osteopontin and body composition in systemic lupus erythematosus: a cross-sectional study.

Panminerva medica·2026
Same journal

Fluid de-resuscitation in critical illness: are we measuring the right endpoint?

Panminerva medica·2026
Same journal

A standardized Ferula supplement (Menotrack) to prevent symptoms in post-menopause: a 3-month supplement registry.

Panminerva medica·2026
Same journal

Impact of cardiogenic shock on outcomes in patients with spontaneous coronary artery dissection: a systematic review and meta-analysis.

Panminerva medica·2026
Same journal

Characteristics and outcomes of spontaneous coronary artery dissection versus Takotsubo Syndrome: a systematic review and meta-analysis.

Panminerva medica·2026
Same journal

Medical decluttering: what it is and why it is important.

Panminerva medica·2026
See all related articles

New anticoagulant drugs are being developed to overcome the limitations of current treatments like heparin and warfarin. These novel agents target specific parts of the coagulation pathway, aiming for improved safety and effectiveness in preventing blood clots.

Area of Science:

  • Pharmacology and Medicine
  • Hematology
  • Drug Development

Background:

  • Current anticoagulants, heparin and warfarin, have significant limitations including narrow therapeutic ranges, monitoring requirements, drug/food interactions, parenteral administration, and adverse reactions like heparin-induced thrombocytopenia.
  • These limitations necessitate the development of safer and more effective anticoagulant therapies for treating and preventing thromboembolic events and acute coronary syndromes.

Purpose of the Study:

  • To review emerging anticoagulant agents, detailing their pharmacological and clinical properties.
  • To analyze the mechanisms of action within the coagulation pathway for these novel agents.
  • To examine clinical trial data informing new anticoagulation strategies.

Main Methods:

  • Literature review of pharmacological and clinical properties of new anticoagulant agents.

Related Experiment Videos

  • Analysis of the coagulation pathway targets for novel anticoagulants.
  • Review of clinical trial outcomes for new anticoagulation strategies.

    • Main Results:

    • Identified new anticoagulant classes under investigation: direct thrombin inhibitors, indirect activated factor X inhibitors, and inhibitors of tissue factor and activated factor VII.
    • These agents target specific points in the coagulation cascade, offering potential advantages over existing therapies.

    Conclusions:

    • Novel anticoagulant agents show promise for improved effectiveness, safety, convenience, and cost-effectiveness compared to current treatments.
    • Further clinical evaluation is crucial to establish new anticoagulation strategies and optimize patient care.